<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">NADOLOL</span><br/>(nay-doe'lole)<br/><span class="topboxtradename">Corgard<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">beta-adrenergic antagonist (sympatholytic, adrenergic blocking agent)</span>; <span class="classification">antihypertensive</span><br/><b>Prototype: </b>Propranolol<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>20 mg, 40 mg, 80 mg, 120 mg, 160 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Nonselective beta-adrenergic blocking agent pharmacologically and chemically similar to propranolol. Inhibits response to
         adrenergic stimuli by competitively blocking beta-adrenergic receptors within heart.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Reduces heart rate and cardiac output at rest and during exercise, and also decreases conduction velocity through AV node
         and myocardial automaticity. Decreases both systolic and diastolic BP at rest and during exercise. Suppression of beta<sub>2</sub>-adrenergic receptors in bronchial and vascular smooth muscle can cause bronchospasm and a Raynaud's-like phenomenon.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Hypertension, either alone or in combination with a diuretic. Also long-term prophylactic management of angina pectoris.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Bronchial asthma, severe COPD, inadequate myocardial function, sinus bradycardia, greater than first-degree conduction block,
         overt cardiac failure, cardiogenic shock. Safety during pregnancy (category C), lactation, and in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>CHF; diabetes mellitus; hyperthyroidism; renal impairment.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertension, Angina</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 40 mg once/d, may increase up to 240320 mg/d in 12 divided doses<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<p>
         			Note: Dose is usually titrated up in 4080 mg increments until optimum dose is achieved.
         		
      </p><span class="adminroutetype">Oral</span><br/><ul>
<li>Do not discontinue abruptly; reduce dosage over a 12-wk period. Abrupt withdrawal can precipitate MI or thyroid storm
            in susceptible patients.
         </li>
<li>Store at 15°30° C (59°86° F); protect drug from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Hypersensitivity (rash, pruritus, <span class="speceff-life">laryngospasm, respiratory disturbances</span>). <span class="typehead">CV:</span>
<span class="speceff-common">Bradycardia, peripheral vascular insufficiency (Raynaud's type),</span> palpitation, postural hypotension, conduction or rhythm disturbances, CHF. <span class="typehead">GI:</span> Dry mouth. <span class="typehead">CNS:</span>
<span class="speceff-common">Dizziness, fatigue,</span> sedation, headache, paresthesias, behavioral changes. <span class="typehead">Special Senses:</span> Blurred vision, dry eyes. <span class="typehead">Skin:</span> Dry skin. <span class="typehead">Urogenital:</span> Impotence. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">nsaid</span>s may decrease hypotensive effects; may mask symptoms of a hypoglycemic reaction to <b>insulin,</b>
<span class="classification">sulfonylureas</span>; <b>prazosin,</b>
<b>terazosin</b> may increase severe hypotensive response to first dose. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 3040% of PO dose absorbed. <span class="typehead">Peak:</span> 24 h. <span class="typehead">Duration:</span> 1724 h. <span class="typehead">Distribution:</span> Widely distributed; crosses placenta; distributed in breast milk. <span class="typehead">Metabolism:</span> No hepatic metabolism. <span class="typehead">Elimination:</span> 70% excreted in urine; also excreted in feces. <span class="typehead">Half-Life:</span> 1024 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Assess heart rate and BP before administration of each dose. Withhold drug and notify physician if apical pulse drops below
            60 bpm or systolic BP below 90 mm Hg.
         </li>
<li>Monitor weight. Advise patient to report weight gain of 11.5 kg (23 lb) in a day and any other possible signs
            of CHF (e.g., cough, fatigue, dyspnea, rapid pulse, edema).
         </li>
<li>Evaluate effectiveness for patients with angina by reduction in frequency of anginal attacks and improved exercise tolerance.
            Improvement should coincide with steady state serum concentration reached within 69 d. Keep physician informed of drug
            effect.
         </li>
<li>Monitor patients with diabetes mellitus closely. Beta-adrenergic blockade produced by nadolol may prevent important clinical
            manifestations of hypoglycemia (e.g., tachycardia, BP changes).
         </li>
<li>Monitor I&amp;O ratio and creatinine clearance in patients with impaired kidney function or with cardiac problems. Dosage intervals
            will be lengthened with decreases in creatinine clearance.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Check pulse before taking each dose. Do not take your medication if pulse rate drops below 60 (or other parameter set by physician)
            or becomes irregular. Consult your physician right away.
         </li>
<li>Do not stop taking your medication or alter dosage without consulting your physician.</li>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>